Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

LVGN7409

Phase 1Biologic

LLyvgen Biopharma Holdings Limited

LVGN7409 is one of 25 biologic programs targeting Metastatic. It is currently in Phase 1.

1

Indications

2

Total Trials

1

Active Trials

24

Competitors

Pipeline

Status by Indication[3][1]

Indication

MetastaticActive, not recruiting

MetastaticPhase 1

Active, not recruiting

Competition

Competitive Landscape

27 competitors in Metastatic

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Keytruda

Tecentriq

Trodelvy

Padcev

Erbitux

Jemperli

GGlaxo Dba Glaxosmithkline

Imbruvica

PPharmacyclics LLC.

Zejula

GGlaxo Dba Glaxosmithkline

JMKX001899

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Refractory Malignancy1 trial

Study of LVGN7409 (CD40 Agonist Antibody) in Locally Advanced, Metastatic or Recurrent/Refractory Malignancy

Completed·LLyvgen Biopharma Holdings Limited·Phase 1·NCT05152212·33 enrolled

Metastatic1 trial

Phase 1 Trial of LVGN7409 (CD40 Agonist Antibody) as Single Agent and Combination Therapies in Advanced or Metastatic Malignancy

Active, not recruiting·LLyvgen Biopharma Holdings Limited·Phase 1·NCT04635995·126 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for LVGN7409. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LVGN7409 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LVGN7409. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Lyvgen Biopharma Holdings Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: LLyvgen Biopharma Holdings Limited

Related News